Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Overview of attention for article published in Frontiers in oncology, October 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 15,526 followers.

RT @koshkin85: Keynote 427 supports ICI monotherapy in frontline #RCC. Recent paper with @PBarataMD @bilenma provides real world data @Kidn…

RT @koshkin85: Keynote 427 supports ICI monotherapy in frontline #RCC. Recent paper with @PBarataMD @bilenma provides real world data @Kidn…

Tagging for #kidneycancer #BookClub. Thanks @koshkin85 for sharing!

RT @koshkin85: Keynote 427 supports ICI monotherapy in frontline #RCC. Recent paper with @PBarataMD @bilenma provides real world data @Kidn…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.